2025-12-21 - Analysis Report
Okay, here's a breakdown of the information provided for Natera Inc (NTRA), along with analysis:

**1) Return Rate Comparison**

*   **Ticker:** NTRA
*   **Company Overview:** Natera Inc. is a diagnostics company focusing on cell-free DNA testing.
*   **NTRA Cumulative Return:** 137.67%
*   **S&P 500 (VOO) Cumulative Return:** 101.15%
*   **Divergence:** 36.2 (Relative Divergence: 47.4)

**Analysis:** NTRA has significantly outperformed the S&P 500 (VOO) in terms of cumulative return.  The divergence of 36.2 indicates that NTRA's outperformance is substantial. A relative divergence of 47.4 suggests that the current outperformance is somewhat in the middle of its historical range relative to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha    | Beta   | Cap(B) |
|------------|---------|-------|----------|--------|--------|
| 2015-2017  | -10.0%  | 70.1% | -34.0%   | -0.2   | 1.2    |
| 2016-2018  | 22.0%   | 80.0% | 6.0%     | 0.1    | 1.9    |
| 2017-2019  | 50.0%   | 80.0% | 28.0%    | 1.0    | 4.7    |
| 2018-2020  | 186.0%  | 80.5% | 163.0%   | 1.1    | 13.9   |
| 2019-2021  | 96.0%   | 80.5% | 49.0%    | 1.6    | 13.0   |
| 2020-2022  | -77.0%  | 80.5% | -76.0%   | 0.1    | 5.6    |
| 2021-2023  | -194.0% | 76.6% | -195.0%  | -1.1   | 8.7    |
| 2022-2024  | 8.0%    | 76.6% | -13.0%   | -1.2   | 22.1   |
| 2023-2025  | 165.0%  | 76.6% | 99.0%    | 0.1    | 32.4   |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate shows periods of strong growth (e.g., 2018-2020, 2017-2019, 2019-2021 and 2023-2025) and significant decline (e.g., 2021-2023 and 2020-2022), indicating high volatility.
*   **MDD:** The Maximum Drawdown is consistently high, demonstrating substantial risk.
*   **Alpha:** The Alpha values fluctuate significantly, reflecting periods of outperformance (positive Alpha) and underperformance (negative Alpha) relative to the market.
*   **Beta:** The Beta values vary, suggesting changing sensitivity to market movements. A Beta above 1 indicates that the stock tends to amplify market movements, while a Beta below 1 suggests less sensitivity. Negative Betas imply that the stock moves inversely to the market.
*   **Cap(B):** Market Cap increasing from 1.2B to 32.4B shows a growing company with possible rapid expansion.

**2) Recent Stock Price Fluctuations**

*   **Close:** 231.96
*   **Last-market:** price: 231.96, previousClose: 224.74, change: 3.21
*   **5-day SMA:** 227.60
*   **20-day SMA:** 234.5
*   **60-day SMA:** 203.50

**Analysis:**

*   The recent closing price is slightly below the 20-day SMA, but above the 5-day SMA, suggesting that the recent trend is upward.  The 60-day SMA is significantly lower, indicating a strong uptrend over the past couple of months. The positive change from the previous close of 3.21 shows a positive momentum.

**3) RSI, PPO, MRI, and Expected Return**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 42.84
*   **PPO:** -1.26
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -2.4 (short-term decline)
*   **Expected Return (%):** -50.6 (long-term excess return compared to S&P 500 if invested long-term)

**Analysis:**

*   The MRI suggests a medium investment risk.
*   The RSI of 42.84 is neutral, not indicating overbought or oversold conditions.
*   The negative PPO suggests that the short-term moving average is trending below the long-term moving average, which can be considered a short-term bearish signal.
*   The hybrid signal recommends investing all available cash and reinvestment every month.
*   The negative relative divergence change indicates a recent short-term downward trend compared to VOO.
*   The negative expected return suggests a negative outlook for the stock in the long term when compared to VOO.

**4) Recent News & Significant Events**

*   **Positive:**
    *   Orion Porfolio Solutions LLC bought shares of NTRA.
    *   Barclays Raises Natera (NTRA) Price Target to $270
    *   Blood test helps spot colon cancer patients who gain from celecoxib.
    *   Strong New Signatera ctDNA Data Just Shift Natera’s (NTRA) Investment Narrative?
*   **Neutral/Mixed:**
    *   Assessing Valuation After a Multi‑Year Share Price Surge
    *   Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins

**Analysis:** The recent news is a mix of positive and neutral/mixed sentiment.  The analyst's raised price target and new share acquisition are positive signals.  The articles about Signatera data and its impact on colon cancer treatment are also positive for Natera's potential. The "Hold" rating suggests caution, acknowledging both growth and potential overvaluation.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.47)
*   **Opinions:** 19
*   **Target Price:** Avg: 244.42 / High: 280.00 / Low: 186.00
*   **Recent Rating Changes:** No changes available

**Analysis:** The analyst consensus is a "Strong Buy," and the average target price of $244.42 indicates potential upside from the current price.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2025-11-07 | -0.64 | 0.59 B$    |
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.5  | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2025-11-07 | -0.26 | 0.44 B$    |

**Analysis:**

*   The company is not yet profitable, as indicated by the negative EPS values.  However, revenue is generally increasing, suggesting growth.
*   It is worth noting that 2 different values exist for 2025-11-07.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-09-30 | $0.59B     | 64.91%        |
| 2025-06-30 | $0.55B     | 63.41%        |
| 2025-03-31 | $0.50B     | 63.12%        |
| 2024-12-31 | $0.48B     | 62.94%        |
| 2024-09-30 | $0.44B     | 61.79%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE     |
|------------|------------|---------|
| 2025-09-30 | $1.25B     | -6.99%  |
| 2025-06-30 | $1.25B     | -8.10%  |
| 2025-03-31 | $1.24B     | -5.40%  |
| 2024-12-31 | $1.20B     | -4.50%  |
| 2024-09-30 | $0.88B     | -3.60%  |

**Analysis:**

*   Revenue is consistently growing, and the profit margin is high and improving.
*   Equity is increasing, indicating strengthening of the company's financial foundation.
*   The negative ROE reflects the company's current lack of profitability, despite revenue growth and high profit margins.

**7) Comprehensive Analysis (Summary)**

Natera (NTRA) presents a mixed picture.

*   **Positives:**
    *   Significant outperformance vs. S&P 500 historically.
    *   Strong revenue growth and high profit margins.
    *   Positive news catalysts (analyst upgrades, potential of Signatera data, new investment).
    *   Strong Buy analyst consensus with upside target price.
*   **Negatives:**
    *   High historical volatility (MDD).
    *   Currently unprofitable (negative EPS and ROE).
    *   Negative expected long-term return compared to S&P 500.
    *   Recent short-term downward trend.
    *   Potential overvaluation.

**Overall:**  Natera appears to be a high-growth, high-risk stock.  Its cutting-edge technology and expanding revenue base are promising. However, the lack of profitability, high volatility, and mixed analyst sentiment suggest that a cautious approach is warranted. The recent market data indicates a medium level investment as the expected return is negative. The market risk indicator is medium suggesting a balanced investment. The hybrid signal recommending reinvesting on cash suggests to hold on the stock. The company is expected to become more valuable based on strong buy consensus from analyst reviews.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.